Ticagrelor after MI: Sometimes less is more

Sarah Sipek | | Cardiovascular Business | Interventional Cardiology

Ticagrelor—a platelet aggregation inhibitor—gained FDA approval in February 2016 for use with low-dose acetylsalicylic acid (ASA) in adults who had suffered a myocardial infarction a year or more ago. However, its safety is now being calling into question.

The German Institute for Quality and Efficiency in Health Care found that adding ticagrelor to ASA drug therapy increased incidents of non-severe bleeding.

Furthermore, manufacturers were not able to produce data showing that quality of life increased with concurrent ticagrelor treatment. 

Sarah Sipek

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup